Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses

  • Pérez Ramírez, Patricia
  • Astorgano, David
  • Albericio, Guillermo
  • Flores, Sara
  • Sánchez-Corzo, Cristina
  • Noriega, María A.
  • Sánchez-Cordón, Pedro J.
  • Labiod, Nuria
  • Delgado, Rafael
  • Casasnovas, José María
  • Esteban, Mariano
  • García-Arriaza, Juan
Despite the decrease in mortality and morbidity due to SARS-CoV-2 infection, the incidence of infections due to Omicron subvariants of SARS-CoV-2 remains high. The mutations acquired by these subvariants, mainly concentrated in the receptor-binding domain (RBD), have caused a shift in infectivity and transmissibility, leading to a loss of effectiveness of the first authorized COVID-19 vaccines, among other reasons, by neutralizing antibody evasion. Hence, the generation of new vaccine candidates adapted to Omicron subvariants is of special interest in an effort to overcome this immune evasion. Here, an optimized COVID-19 vaccine candidate, termed MVA-S(3P_BA.1), was developed using a modified vaccinia virus Ankara (MVA) vector expressing a full-length prefusion-stabilized SARS-CoV-2 spike (S) protein from the Omicron BA.1 variant. The immunogenicity and efficacy induced by MVA-S(3P_BA.1) were evaluated in mice in a head-to-head comparison with the previously generated vaccine candidates MVA-S(3P) and MVA-S(3Pbeta), which express prefusion-stabilized S proteins from Wuhan strain and Beta variant, respectively, and with a bivalent vaccine candidate composed of a combination of MVA-S(3P) and MVA-S(3P_BA.1). The results showed that all four vaccine candidates elicited, after a single intramuscular dose, protection of transgenic K18-hACE2 mice challenged with SARS-CoV-2 Omicron BA.1, reducing viral loads, histopathological lesions, and levels of proinflammatory cytokines in the lungs. They also elicited anti-S IgG and neutralizing antibodies against various Omicron subvariants, with MVA-S(3P_BA.1) and the bivalent vaccine candidate inducing higher titers. Additionally, an intranasal immunization in C57BL/6 mice with all four vaccine candidates induced systemic and mucosal S-specific CD4+ and CD8+ T-cell and humoral immune responses, and the bivalent vaccine candidate induced broader immune responses, eliciting antibodies against the ancestral Wuhan strain and different Omicron subvariants. These results highlight the use of MVA as a potent and adaptable vaccine vector against new emerging SARS-CoV-2 variants, as well as the promising feature of combining multivalent MVA vaccine candidates., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was supported by Fondo COVID-19 grant COV20/00151 (Spanish Health Ministry, Instituto de Salud Carlos III (ISCIII)), Fondo Supera COVID-19 grant (Crue Universidades-Banco Santander), CSIC grant 202120E079, grant CNS2022-135511 funded by the Spanish Ministry of Science, Innovation and Universities (MCIU)/Spanish Research Agency (AEI)/10.13039/501100011033 and by the European Union NextGenerationEU/PRTR to promote the consolidation of research, and funds from Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC) co-financed with FEDER funds (to JG-A); CSIC grant 2020E84, la Caixa Banking Foundation grant CF01-00008, Ferrovial, and MAPFRE donations (to ME); and Spanish MCIU/AEI/10.13039/501100011033 grant PID2020-114481RB-I00 (to JG-A and ME). This research work was also funded by the European Commission-NextGenerationEU, through CSIC’s Global Health Platform (PTI Salud Global) (to JG-A and ME). JG-A also received grants from the European Commission HORIZON-HLTH-2023-DISEASE-03-18 (Project MARVAX: 101137183 and Project FLAVIVACCINE: 101137006). JG-A and ME also acknowledges financial support from the Spanish AEI/10.13039/501100011033, through the “Severo Ochoa” Programme for Centres of Excellence in R&D (SEV-2013-0347, SEV-2017-0712). JC acknowledges MCIU and CSIC support (project number 202020E079). RD received grants from ISCIII (FIS PI2100989), the European Commission Horizon 2020 Framework Programme (Project VIRUSCAN FETPROACT-2016: 731868 and Project EPIC-CROWN-2: 101046084), and Fundación Caixa-Health Research HR18-00469 (Project StopEbola). The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Immunogenicity and efficacy of homologous and heterologous NDV and MVA SARS-CoV-2 vaccines in mice and hamsters

  • Pérez, Patricia
  • Jiang, Kaijun
  • González-Domínguez, Irene
  • Rodríguez-Martín, Daniel
  • Abdeljawad, Adam
  • Cupic, Anastasija
  • Slamanig, Stefan
  • Flores, Sara
  • Noriega, María A
  • Sánchez-Cordón, Pedro J.
  • Lemus, Nicholas
  • Lai, Tsoi Ying
  • Sun, Weina
  • Esteban, Mariano
  • García-Sastre, Adolfo
  • García-Arriaza, Juan
Effective vaccination strategies adaptable to emerging viruses like SARS-CoV-2 and capable of inducing robust protective immunity are needed. We evaluated the immunogenicity and protective efficacy of homologous and heterologous prime/boost regimens against SARS-CoV-2 in K18-hACE2 mice and Syrian hamsters using Newcastle disease virus (NDV-HXP-S, intranasal) and modified vaccinia virus Ankara (MVA-S(3P), intramuscular) vectors encoding a prefusion-stabilized SARS-CoV-2 spike (S) protein. All regimens protected against weight loss and markedly reduced viral replication and lung pathology. Vaccination induced serum anti-S and anti-receptor binding domain IgGs and neutralizing antibodies against ancestral virus and variants. In mice, mucosal anti-S IgA and IgG were detected after NDV-HXP-S immunization. Homologous MVA-S(3P)/MVA-S(3P) and heterologous NDV-HXP-S/MVA-S(3P) elicited higher polyfunctional systemic T-cell responses, while homologous NDV-HXP-S/NDV-HXP-S induced stronger pulmonary CD8+ T cells. Hamsters vaccinated with NDV-HXP-S exhibited protection of the upper respiratory tract, with the NDV-HXP-S/MVA-S(3P) regimen showing a trend toward reduced direct contact transmission of SARS-CoV-2. These findings demonstrate the capacity of NDV and MVA vector platforms to induce robust systemic and mucosal antigen-specific humoral and T-cell responses against SARS-CoV-2, contributing to protection against both disease and transmission, and support further exploration of these vector platforms for vaccination against SARS-CoV-2 and potentially other pathogens., This research was supported by CSIC grant 202120E079, grant funded by the Spanish Ministry of Science, Innovation and Universities (MCIU)/Spanish Research Agency (AEI)/10.13039/501100011033 and by the European Union NextGenerationEU/PRTR to promote the consolidation of research, and funds from Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC) co-financed with FEDER funds (to J.G.-A.); CSIC grant 2020E84 (to M.E.); Spanish MCIU/AEI/10.13039/501100011033 grant PID2020-114481RB-I00 (to J.G.-A. and M.E.). This work was also partly supported by CRIPT (Center for Research on Influenza Pathogenesis and Transmission), an NIAID-funded Center of Excellence for Influenza Research and Response (CEIRR, contract # 75N93021C00014) (to A.G.-S.). This works is also supported by seed funding awarded by ISMMS Department of Microbiology (to W.S.). This research work was also funded by the European Commission-NextGenerationEU, through CSIC’s Global Health Platform (PTI Salud Global) (to J.G.-A. and M.E.). J.G.-A. also received grants from the European Commission HORIZON-HLTH-2023-DISEASE-03-18 (Project MARVAX: 101137183 and Project FLAVIVACCINE: 101137006). J.G.-A. and M.E. also acknowledges financial support from the Spanish AEI/10.13039/501100011033, through the “Severo Ochoa” Programme for Centres of Excellence in R&D (SEV-2017-0712, CEX2023-001386-S). The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Homologous MVA and heterologous DREP/MVA vaccine regimens induce robust and durable immune responses against SARS-CoV-2

  • Pérez, Patricia
  • Esteso, Gloria
  • Noriega, María A.
  • Vidakovics, Laura Perez
  • Liljeström, Peter
  • McInerney, Gerald M
  • Esteban, Mariano
  • García-Arriaza, Juan
Despite the success of current COVID-19 vaccines, the immunity they generate wanes over time, requiring periodic boosters. The limited durability of memory responses, particularly from mRNA vaccines, remains a major challenge for achieving long-term protection. Developing vaccines that induce more sustained immunity would lessen the need for frequent revaccination, improving global vaccination logistics, especially in resource-limited settings. DNA-launched self-amplifying RNA replicons (DREP) and modified vaccinia virus Ankara (MVA) vectors are promising vaccine platforms capable of inducing potent humoral and cellular immunity. In this study, we evaluated SARS-CoV-2-specific immune responses in C57BL/6 mice following homologous and heterologous prime/boost regimens combining DREP- and MVA-based vaccines expressing the spike (S) protein from either the ancestral Wuhan strain or the Omicron XBB.1.5 variant. Homologous (DREP/DREP, MVA/MVA) and heterologous (DREP/MVA) regimens were followed for six months. MVA-S(3P)-based boosters elicited robust and durable anti-S IgG antibodies cross-recognizing multiple variants, with minimal decay over time. Neutralization mapped to the booster antigen: MVA-S(3PWuhan) induced neutralization of the ancestral strain, while MVA-S(3PXBB.1.5) selectively neutralized Omicron subvariants, maintaining high titers for at least six months. MVA-S(3P) boosters also enhanced antibody Fc-effector functions, memory B cells, and T follicular helper responses. Early after boosting, heterologous DREP/MVA regimens induced stronger CD4⁺ and CD8⁺ T-cell responses, while at six months all MVA-S(3P)-boosted groups maintained superior, long-lived cellular immunity. Collectively, MVA-S(3P)-based boosters improved the magnitude, breadth, and durability of humoral and cellular responses, supporting their strategic use in homologous and heterologous DREP/MVA vaccination regimens against SARS-CoV-2 and emerging variants., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was supported by CSIC grant 202120E079, grant CNS2022-135511 funded by the Spanish Ministry of Science, Innovation and Universities (MCIU)/Spanish Research Agency (AEI)/https://doi.org/10.13039/501100011033 and by the European Union NextGenerationEU/PRTR to promote research consolidation, as well as funds from the Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC) co-financed with FEDER funds (to JG-A). Additional support was provided by CSIC grant 2020E84 (to ME), and by Spanish MCIU/AEI/https://doi.org/10.13039/501100011033 grant PID2020-114481RB-I00 (to JG-A and ME). This research work also received funding from the European Commission-NextGenerationEU, through CSIC’s Global Health Platform (PTI Salud Global) (to JG-A and ME). JG-A received further funding from the European Commission HORIZON-HLTH-2023-DISEASE-03-18 (Project MARVAX: 101137183 and Project FLAVIVACCINE: 101137006). JG-A and ME also acknowledge financial support from the Spanish AEI/https://doi.org/10.13039/501100011033 through the “Severo Ochoa” Programme for Centres of Excellence in R&D (SEV-2017-0712, CEX2023-001386-S). The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication., Peer reviewed, Modelo experimental animal, Mamíferos - Roedores